Evidence map›Paper›PMID 32964204›Full record

ArticleKidney medicine

Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan.

Manuel A Anderegg, Nasser A Dhayat, Grit Sommer, Mariam Semmo, Uyen Huynh-Do, Bruno Vogt, Daniel G Fuster

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases.Journal of the American Society of Nephrology : JASN · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?Clinical journal of the American Society of Nephrology : CJASN · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manuel A AndereggDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Nasser A DhayatDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Grit SommerPediatric Endocrinology, Diabetology and Metabolism, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Mariam SemmoDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Uyen Huynh-DoDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Bruno VogtDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Daniel G FusterDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RATIONALE &

objectiveThe impact of tolvaptan on health-related quality-of-life (HRQoL) in patients with autosomal dominant polycystic kidney disease (ADPKD) is unknown. To address this knowledge gap, we studied patient-reported HRQoL in patients enrolled in the Bern ADPKD registry. STUDY

designProspective cohort study. SETTINGS &

participantsInclusion criteria were age 18 years or older, clinical diagnosis of ADPKD, and informed consent. The main exclusion criterion was need for kidney replacement therapy. OUTCOME: HRQoL was assessed using the standardized Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire at start of the study (baseline) and after 1 year (follow-up). The KDQOL-SF has 2 parts: a generic 36-Item Health Survey instrument with 8 subscores and 2 summary scores and a kidney disease-specific instrument to assess health concerns. Higher scores indicate better HRQoL. The influence of tolvaptan treatment on HRQoL and kidney-specific health concerns was analyzed using analysis of covariance, adjusting for HRQoL and health concerns before the start of the study, sex, and age.

resultsIn 38 of 121 registry patients, tolvaptan treatment was initiated. Within the first 3 months, treatment had to be discontinued in 6 (16%) patients due to aquaretic side effects (n = 4; 11%) or elevated liver enzyme levels (n = 2; 5%), and a dose reduction was necessary in 8 (21%) patients. We included 98 patients (30 with and 68 without tolvaptan treatment) in the analysis for which baseline and 1-year follow-up data were available. At follow-up, and after adjusting for baseline scores, sex, and age, HRQoL and kidney-specific health concerns were not influenced by tolvaptan treatment, except for patient satisfaction, which was increased. LIMITATIONS: Observational study design, monocentric study at tertiary referral hospital, almost exclusively white study population, grant support by Otsuka Pharmaceuticals.

conclusionsOur results indicate that tolvaptan does not significantly affect HRQoL in patients with ADPKD who tolerate treatment beyond the first 3 months of therapy.

Indexed as

ADPKDHRQoLquality of lifetolvaptan

Identifiers

PMID32964204
PMCPMC7487949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.